<ul>
<li><strong>预计下周将为首位患者进行鼻用 Foralumab 给药</strong></li>
<li><strong>PET 扫描显示接受 Leqembi®（Lecanemab）抗淀粉样蛋白治疗的阿尔茨海默病患者存在未治疗的神经炎症</strong></li>
</ul>
<p>波士顿，2025 年 12 月 12 日（全球新闻稿）——Tiziana Life Sciences, Ltd.（纳斯达克：TLSA）（“Tiziana” 或 “公司”），一家开发突破性免疫调节疗法的生物技术公司，其主要开发候选药物为鼻用 foralumab，这是一种完全人源的抗 CD3 单克隆抗体，宣布其第二阶段随机、安慰剂对照的早期阿尔茨海默病临床试验已开始招募，并计划下周为首位患者给药。</p>
<p>第二阶段临床试验将评估鼻用 foralumab 作为单药治疗和与 FDA 批准的抗淀粉样蛋白治疗药物 lecanemab 或 donanemab 联合使用在早期阿尔茨海默病（AD）患者中的效果。试验中首批筛选参与者的基线临床评估、认知测试、TSPO-PET 成像和液体生物标志物已完成。</p>
<p>临床试验的启动得到了新的 TSPO-PET 成像证据的支持，该证据表明尽管接受了 lecanemab 治疗，但阿尔茨海默病患者的微胶质细胞仍持续广泛激活，确认神经炎症在淀粉样斑块减少后仍然存在。Lecanemab 由 Eisai 和 Biogen 以 Leqembi®的名义上市，是 FDA 批准的两种用于治疗早期阿尔茨海默病的抗淀粉样蛋白疗法之一，已证明能够减少β-淀粉样蛋白斑块。</p>
<p><strong>图 1.</strong> 使用 lecanemab 治疗的阿尔茨海默病患者的 TSPO-PET 扫描，显示大脑中微胶质细胞持续广泛激活。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png"/></p>
<p>Tiziana 科学顾问委员会主席、布莱根妇女医院神经疾病安·罗姆尼中心的共同主任 Howard Weiner 博士表示：“这一 PET 发现是一个关键的见解：清除淀粉样蛋白并不会关闭大脑的炎症反应。我们相信鼻用 foralumab 直接针对这种残余的神经炎症，通过诱导调节性 T 细胞迁移到大脑并平息激活的微胶质细胞——这一机制我们已经证明能够减少继发性进展性多发性硬化症中的微胶质细胞激活。”</p>
<p><strong>图 2.</strong> 鼻用 foralumab 治疗的多发性硬化症患者的 TSPO-PET 扫描，显示在 6 个月的治疗期间微胶质细胞激活显著减少。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png"/></p>
<p><strong>第二阶段试验设计与理由</strong></p>
<p>该研究将评估鼻用 foralumab 是否：</p>
<ul>
<li>作为单药治疗，减少微胶质细胞激活并通过抑制神经炎症减缓认知衰退。</li>
<li>与 lecanemab 或 donanemab 联合使用时，是否通过同时针对淀粉样病理和持续的微胶质细胞炎症提供附加或协同效益。</li>
</ul>
<p>“随着招募工作的展开，基线神经影像学和生物标志物的获取，我们即将测试一种根本新的阿尔茨海默病治疗方法——一种治疗与持续神经退行性变相关的慢性脑炎症的方法。我们预计首位患者将在几天内开始给药，” Tiziana Life Sciences 首席执行官 Ivor Elrifi 表示。“这一里程碑标志着测试免疫调节单独或与淀粉样去除结合是否能够实现疾病修饰的重要一步。无论是否接受抗淀粉样蛋白治疗，阿尔茨海默病中的炎症 PET 证据为这一创新策略提供了明确的生物学依据。”</p>
<p>鼻用 foralumab 是一种完全人源的抗 CD3 单克隆抗体，旨在诱导调节性 T 细胞并抑制病理性神经炎症，使其成为解决阿尔茨海默病中即使在淀粉样清除后仍然活跃的炎症成分的潜在首创疗法。</p>
<p><strong>关于第二阶段试验</strong></p>
<p>第二阶段研究旨在评估鼻用 foralumab 作为单药治疗和与 lecanemab 或 donanemab 联合使用在早期/轻度阿尔茨海默病中的安全性、耐受性和有效性。关键终点将包括神经炎症的测量（通过 TSPO-PET 成像）、认知功能和与淀粉样蛋白和 tau 病理相关的生物标志物变化。该试验的结果将为未来的发展提供信息，并可能建立一种新的治疗阿尔茨海默病的范式，单独针对神经炎症或与抗淀粉样蛋白治疗结合使用。</p>
<p><strong>关于 Foralumab</strong></p>
<p>Foralumab 是一种完全人源的抗 CD3 单克隆抗体，是一种生物药物候选者，已显示在鼻用给药时刺激 T 调节细胞。目前，已有 14 名非活动性继发性进展性多发性硬化症（na-SPMS）患者在开放标签的中型扩展使用（EA）项目（NCT06802328）中接受了给药，所有患者在 6 个月内均出现了疾病改善或稳定。此外，鼻用 foralumab 目前正在一项针对非活动性继发性进展性多发性硬化症患者的第二阶段随机、双盲、安慰剂对照、多中心剂量范围试验中进行研究（NCT06292923）。</p>
<p>Foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体（mAb）。鼻用 foralumab 的免疫调节代表了治疗神经炎症和神经退行性人类疾病的新途径。[1],[2]</p>
<p><strong>关于 Tiziana Life Sciences</strong></p>
<p>Tiziana Life Sciences 是一家临床阶段的生物制药公司，开发突破性疗法，利用变革性的药物递送技术实现替代免疫疗法。Tiziana 创新的鼻用给药方法有潜力在疗效、安全性和耐受性方面提供比静脉（IV）给药更好的改善。Tiziana 的主要候选药物鼻用 foralumab 是目前唯一在临床开发中的全人源抗 CD3 单克隆抗体，已在研究中显示出良好的安全性和临床反应。Tiziana 的替代免疫疗法技术已获得专利，多个申请正在等待中，预计将允许广泛的管线应用。</p>
<p>有关 Tiziana Life Sciences 及其创新疗法管线的更多信息，请访问 www.tizianalifesciences.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告中所作的某些声明为前瞻性声明。这些前瞻性声明不是历史事实，而是基于公司当前的期望、估计和对其行业的预测、信念和假设。诸如 “预期”、“期望”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语旨在识别前瞻性声明。这些声明并不保证未来的表现，并且受到已知和未知的风险、不确定性和其他因素的影响，其中一些超出了公司的控制范围，难以预测，可能导致实际结果与前瞻性声明中表达或预测的结果有重大差异。公司提醒证券持有者和潜在证券持有者不要对这些前瞻性声明过于依赖，这些声明仅反映公司在本公告日期的观点。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：与市场条件相关的不确定性以及在 Tiziana 截至 2024 年 12 月 31 日的 20-F 表年度报告中更全面描述的其他因素，以及向证券交易委员会提交的其他定期报告。本公告中所作的前瞻性声明仅与声明作出之日的事件相关。除法律或任何适当监管机构要求外，公司不承担公开发布任何修订或更新这些前瞻性声明以反映公告日期后发生的事件、情况或意外事件的义务。</p>
<p><strong>如需进一步咨询：</strong></p>
<p><strong>Tiziana Life Sciences Ltd</strong></p>
<p>Paul Spencer，业务发展与投资者关系</p>
<p>+44 (0) 207 495 2379</p>
<p>电子邮件：info@tizianalifesciences.com</p>
<p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<p>本公告附带的照片可在以下网址获取</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

TLSA

<p>Tiziana Life Sciences 计划在下周为其第二阶段阿尔茨海默病试验的首位患者给药。该试验将评估鼻用 foralumab，既作为单药治疗，也与抗淀粉样蛋白疗法 lecanemab 或 donanemab 联合使用。该研究旨在解决阿尔茨海默病患者的神经炎症问题，可能提供一种新的治疗范式。基线评估和影像学检查已完成，试验将重点关注安全性、有效性和认知功能的改善</p>

<ul>
<li><strong>First Patient Expected to be Dosed Next Week with Intranasal Foralumab</strong></li>
<li><strong>PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi</strong> <strong>®</strong> <strong>(Lecanemab) Anti-Amyloid Therapy</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>预计下周将为首位患者进行鼻用 Foralumab 给药</strong></li>
<li><strong>PET 扫描显示接受 Leqembi®（Lecanemab）抗淀粉样蛋白治疗的阿尔茨海默病患者存在未治疗的神经炎症</strong></li>
</ul>
</div><p>BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s clinical trial and plans to dose the first patient next week.</p>
<div class="lb-trans"><p>波士顿，2025 年 12 月 12 日（全球新闻稿）——Tiziana Life Sciences, Ltd.（纳斯达克：TLSA）（“Tiziana” 或 “公司”），一家开发突破性免疫调节疗法的生物技术公司，其主要开发候选药物为鼻用 foralumab，这是一种完全人源的抗 CD3 单克隆抗体，宣布其第二阶段随机、安慰剂对照的早期阿尔茨海默病临床试验已开始招募，并计划下周为首位患者给药。</p>
</div><p>The Phase 2 clinical trial will evaluate intranasal foralumab both as monotherapy and in combination with an FDA approved anti-amyloid therapy, lecanemab or donanemab, in patients with early Alzheimer’s disease (AD). Baseline clinical assessments, cognitive testing, TSPO-PET imaging, and fluid biomarkers have been completed in the first participants screened in the trial.</p>
<div class="lb-trans"><p>第二阶段临床试验将评估鼻用 foralumab 作为单药治疗和与 FDA 批准的抗淀粉样蛋白治疗药物 lecanemab 或 donanemab 联合使用在早期阿尔茨海默病（AD）患者中的效果。试验中首批筛选参与者的基线临床评估、认知测试、TSPO-PET 成像和液体生物标志物已完成。</p>
</div><p>The clinical trial launch is supported by new TSPO-PET imaging evidence demonstrating persistent and widespread microglial activation in an Alzheimer’s patient despite treatment with lecanemab, confirming that neuroinflammation remains present even after amyloid plaque reduction. Lecanemab, marketed by Eisai and Biogen as Leqembi®, is one of the two FDA-approved anti-amyloid therapies for treating early Alzheimer’s and is proven to reduce beta-amyloid plaques.</p>
<div class="lb-trans"><p>临床试验的启动得到了新的 TSPO-PET 成像证据的支持，该证据表明尽管接受了 lecanemab 治疗，但阿尔茨海默病患者的微胶质细胞仍持续广泛激活，确认神经炎症在淀粉样斑块减少后仍然存在。Lecanemab 由 Eisai 和 Biogen 以 Leqembi®的名义上市，是 FDA 批准的两种用于治疗早期阿尔茨海默病的抗淀粉样蛋白疗法之一，已证明能够减少β-淀粉样蛋白斑块。</p>
</div><p><strong>Figure 1.</strong> TSPO-PET scan of an Alzheimer’s patient treated with lecanemab demonstrating persistent and widespread microglial activation throughout the brain.</p>
<div class="lb-trans"><p><strong>图 1.</strong> 使用 lecanemab 治疗的阿尔茨海默病患者的 TSPO-PET 扫描，显示大脑中微胶质细胞持续广泛激活。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png"/></p>
<p>Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham, stated, “This PET finding is a critical insight: clearing amyloid does not turn off the brain’s inflammatory response. We believe intranasal foralumab directly addresses this residual neuroinflammation by inducing regulatory T cells to migrate to the brain and calm activated microglia — a mechanism we have already shown reduces microglial activation in secondary progressive multiple sclerosis.”</p>
<div class="lb-trans"><p>Tiziana 科学顾问委员会主席、布莱根妇女医院神经疾病安·罗姆尼中心的共同主任 Howard Weiner 博士表示：“这一 PET 发现是一个关键的见解：清除淀粉样蛋白并不会关闭大脑的炎症反应。我们相信鼻用 foralumab 直接针对这种残余的神经炎症，通过诱导调节性 T 细胞迁移到大脑并平息激活的微胶质细胞——这一机制我们已经证明能够减少继发性进展性多发性硬化症中的微胶质细胞激活。”</p>
</div><p><strong>Figure 2.</strong> TSPO-PET scans from intranasal foralumab-treated MS patients showing marked reduction in microglial activation over a 6-month treatment period.</p>
<div class="lb-trans"><p><strong>图 2.</strong> 鼻用 foralumab 治疗的多发性硬化症患者的 TSPO-PET 扫描，显示在 6 个月的治疗期间微胶质细胞激活显著减少。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png"/></p>
<p><strong>Phase 2 Trial Design and Rationale</strong></p>
<div class="lb-trans"><p><strong>第二阶段试验设计与理由</strong></p>
</div><p>The study will evaluate whether intranasal foralumab:</p>
<div class="lb-trans"><p>该研究将评估鼻用 foralumab 是否：</p>
</div><ul>
<li>As a monotherapy, reduces microglial activation and slows cognitive decline by suppressing neuroinflammation.</li>
<li>In combination with lecanemab or donanemab will provide additive or synergistic benefit by simultaneously targeting amyloid pathology and persistent microglial inflammation.</li>
</ul>
<div class="lb-trans"><ul>
<li>作为单药治疗，减少微胶质细胞激活并通过抑制神经炎症减缓认知衰退。</li>
<li>与 lecanemab 或 donanemab 联合使用时，是否通过同时针对淀粉样病理和持续的微胶质细胞炎症提供附加或协同效益。</li>
</ul>
</div><p>“With enrolment now underway and baseline neuroimaging and biomarkers secured, we are on the verge of testing a fundamentally new approach to Alzheimer’s — one that treats the chronic brain inflammation that is associated with ongoing neurodegeneration. We expect the first patients to begin dosing within days,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This milestone marks an important step toward testing whether immune modulation alone, or in combination with amyloid removal, can achieve disease modification. The PET evidence of inflammation in AD with or without anti-amyloid treatment provides a clear biological rationale for this innovative strategy.”</p>
<div class="lb-trans"><p>“随着招募工作的展开，基线神经影像学和生物标志物的获取，我们即将测试一种根本新的阿尔茨海默病治疗方法——一种治疗与持续神经退行性变相关的慢性脑炎症的方法。我们预计首位患者将在几天内开始给药，” Tiziana Life Sciences 首席执行官 Ivor Elrifi 表示。“这一里程碑标志着测试免疫调节单独或与淀粉样去除结合是否能够实现疾病修饰的重要一步。无论是否接受抗淀粉样蛋白治疗，阿尔茨海默病中的炎症 PET 证据为这一创新策略提供了明确的生物学依据。”</p>
</div><p>Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to induce Tregs and suppress pathological neuroinflammation, positioning it as a potential first-in-class therapy to address the inflammatory component of Alzheimer’s disease that remains active even after amyloid clearance.</p>
<div class="lb-trans"><p>鼻用 foralumab 是一种完全人源的抗 CD3 单克隆抗体，旨在诱导调节性 T 细胞并抑制病理性神经炎症，使其成为解决阿尔茨海默病中即使在淀粉样清除后仍然活跃的炎症成分的潜在首创疗法。</p>
</div><p><strong>About the Phase 2 Trial</strong></p>
<div class="lb-trans"><p><strong>关于第二阶段试验</strong></p>
</div><p>The Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of intranasal foralumab as both a monotherapy and in combination with lecanemab or donanemab in early/mild AD. Key endpoints will include measures of neuroinflammation (via TSPO-PET imaging), cognitive function, and biomarker changes related to amyloid and tau pathology. Results from this trial will inform future development and may establish a new paradigm for treating AD by targeting neuroinflammation alone or in combination with anti-amyloid therapy.</p>
<div class="lb-trans"><p>第二阶段研究旨在评估鼻用 foralumab 作为单药治疗和与 lecanemab 或 donanemab 联合使用在早期/轻度阿尔茨海默病中的安全性、耐受性和有效性。关键终点将包括神经炎症的测量（通过 TSPO-PET 成像）、认知功能和与淀粉样蛋白和 tau 病理相关的生物标志物变化。该试验的结果将为未来的发展提供信息，并可能建立一种新的治疗阿尔茨海默病的范式，单独针对神经炎症或与抗淀粉样蛋白治疗结合使用。</p>
</div><p><strong>About Foralumab</strong></p>
<div class="lb-trans"><p><strong>关于 Foralumab</strong></p>
</div><p>Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).</p>
<div class="lb-trans"><p>Foralumab 是一种完全人源的抗 CD3 单克隆抗体，是一种生物药物候选者，已显示在鼻用给药时刺激 T 调节细胞。目前，已有 14 名非活动性继发性进展性多发性硬化症（na-SPMS）患者在开放标签的中型扩展使用（EA）项目（NCT06802328）中接受了给药，所有患者在 6 个月内均出现了疾病改善或稳定。此外，鼻用 foralumab 目前正在一项针对非活动性继发性进展性多发性硬化症患者的第二阶段随机、双盲、安慰剂对照、多中心剂量范围试验中进行研究（NCT06292923）。</p>
</div><p>Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]</p>
<div class="lb-trans"><p>Foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体（mAb）。鼻用 foralumab 的免疫调节代表了治疗神经炎症和神经退行性人类疾病的新途径。[1],[2]</p>
</div><p><strong>About Tiziana Life Sciences</strong></p>
<div class="lb-trans"><p><strong>关于 Tiziana Life Sciences</strong></p>
</div><p>Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</p>
<div class="lb-trans"><p>Tiziana Life Sciences 是一家临床阶段的生物制药公司，开发突破性疗法，利用变革性的药物递送技术实现替代免疫疗法。Tiziana 创新的鼻用给药方法有潜力在疗效、安全性和耐受性方面提供比静脉（IV）给药更好的改善。Tiziana 的主要候选药物鼻用 foralumab 是目前唯一在临床开发中的全人源抗 CD3 单克隆抗体，已在研究中显示出良好的安全性和临床反应。Tiziana 的替代免疫疗法技术已获得专利，多个申请正在等待中，预计将允许广泛的管线应用。</p>
</div><p>For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</p>
<div class="lb-trans"><p>有关 Tiziana Life Sciences 及其创新疗法管线的更多信息，请访问 www.tizianalifesciences.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</p>
<div class="lb-trans"><p>本公告中所作的某些声明为前瞻性声明。这些前瞻性声明不是历史事实，而是基于公司当前的期望、估计和对其行业的预测、信念和假设。诸如 “预期”、“期望”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语旨在识别前瞻性声明。这些声明并不保证未来的表现，并且受到已知和未知的风险、不确定性和其他因素的影响，其中一些超出了公司的控制范围，难以预测，可能导致实际结果与前瞻性声明中表达或预测的结果有重大差异。公司提醒证券持有者和潜在证券持有者不要对这些前瞻性声明过于依赖，这些声明仅反映公司在本公告日期的观点。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：与市场条件相关的不确定性以及在 Tiziana 截至 2024 年 12 月 31 日的 20-F 表年度报告中更全面描述的其他因素，以及向证券交易委员会提交的其他定期报告。本公告中所作的前瞻性声明仅与声明作出之日的事件相关。除法律或任何适当监管机构要求外，公司不承担公开发布任何修订或更新这些前瞻性声明以反映公告日期后发生的事件、情况或意外事件的义务。</p>
</div><p><strong>For further inquiries:</strong></p>
<div class="lb-trans"><p><strong>如需进一步咨询：</strong></p>
</div><p><strong>Tiziana Life Sciences Ltd</strong></p>
<div class="lb-trans"><p><strong>Tiziana Life Sciences Ltd</strong></p>
</div><p>Paul Spencer, Business Development, and Investor Relations</p>
<div class="lb-trans"><p>Paul Spencer，业务发展与投资者关系</p>
</div><p>+44 (0) 207 495 2379</p>
<div class="lb-trans"><p>+44 (0) 207 495 2379</p>
</div><p>email: info@tizianalifesciences.com</p>
<div class="lb-trans"><p>电子邮件：info@tizianalifesciences.com</p>
</div><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<div class="lb-trans"><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
</div><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<div class="lb-trans"><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
</div><p>Photos accompanying this announcement are available at</p>
<div class="lb-trans"><p>本公告附带的照片可在以下网址获取</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMTM2MCM3MzE5MzM5IzIxMjM4ODU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png" alt="" original-src="https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

Tiziana Life Sciences 将在二期阿尔茨海默症试验中为首位患者用药 | TLSA 股票新闻